Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancer

  • Toshirou Fukushima
  • Yuuki Wakatsuki
  • Takashi Kobayashi
  • Kei Sonehara
  • Kazunari Tateishi
  • Manabu Yamamoto
  • Takeshi Masubuchi
  • Fumiaki Yoshiike
  • Kazuya Hirai
  • Tsutomu Hachiya
  • Tomonobu Koizumi
Original Article

Abstract

Purpose

This phase II study was performed to evaluate the efficacy and safety of cisplatin/pemetrexed combined with 15 mg/kg of bevacizumab followed by pemetrexed/bevacizumab maintenance therapy as first-line chemotherapy in advanced non-squamous non-small cell lung cancer (NSCLC) limited to epidermal growth factor receptor (EGFR)-wild type.

Patients and methods

Fifty patients with advanced or metastatic EGFR-wild type NSCLC aged < 75 years old were enrolled in the study. The patients were treated with four cycles of cisplatin (75 mg/m2, day 1), pemetrexed (500 mg/m2, days 1), and bevacizumab (15 mg/kg, day 1), every 3 weeks, followed by pemetrexed plus bevacizumab maintenance until progression for achieving a response over stable disease after induction chemotherapy.

Results

Partial response and stable disease were observed in 35 (objective response rate: 70, 95% CI: 55.4–82.1%) and 9 patients, respectively, and 39 (78%) patients received pemetrexed plus bevacizumab maintenance therapy. Median progression-free survival and overall survival periods were 12.0 months (95% CI: 7.5–16.5 months) and 31.0 months (95% CI: 22.2–39.8 months), respectively. Grade 3 adverse events included neutropenia (14%), nausea (10%), anorexia (18%), and hypertension (8%). Coagulation disorder was observed in one patient, but all of these events were reversible and resulted in no treatment-related deaths.

Conclusion

The combination of cisplatin/pemetrexed/bevacizumab followed by pemetrexed/bevacizumab maintenance therapy exhibited favorable efficacy and manageable toxicity profiles in patients with EGFR-wild type non-squamous NSCLC (UMIN-CTR number: UMIN000003645).

Keywords

Anti-VEGF agent EGFR-wild type Non-small cell lung cancer Continuation maintenance 

Notes

Acknowledgements

The authors would like to acknowledge the following for their participation in the present study. The investigators and institutions were as follows: Dr. Hiroshi Kuraishi, Nagano Red Cross Hospital; Dr. Tetsuo Kimura and Nobutoshi Morozumi, Saku Central Hospital Advanced Care Center; Dr. Toshihiko Agatsuma, Shinshu Ueda Medical Center; Dr. Akio Morikawa, Showa Inan General Hospital; Dr. Kouji Sakaguchi, Nagano Prefectural Shinshu Medical Center; Dr. Hozumi Tanaka, Iida Hospital; and the Staff of the First Department of Internal Medicine, Shinshu University School of Medicine.

Compliance with ethical standards

Conflict of interest

Dr Koizumi received research grants from AstraZeneca, Ono Pharmaceutical CO., LTD, Chugai Pharmaceutical CO., LTD, outsides the submitted work. The remaining authors declare no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Siegel RL, Miller KD, Jemal A, Cancer statistics, 2017 (2017) CA Cancer J Clin 67:7–30CrossRefPubMedGoogle Scholar
  2. 2.
    Matsuda T, Marugame T, Kamo KI et al (2011) The Japan Cancer Surveillance Research Group. Cancer incidence and incidence rates in Japan in 2005: based on data from 12 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) Project. Jpn J Clin Oncol 41:139–147CrossRefPubMedGoogle Scholar
  3. 3.
    Chan BA, Hughes BG (2015) Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res 4:36–54PubMedPubMedCentralGoogle Scholar
  4. 4.
    Rossi A, Ricciardi S, Maione P, de Marinis F, Gridelli C (2009) Pemetrexed in the treatment of advanced non-squamous lung cancer. Lung Cancer 66:141–149CrossRefPubMedGoogle Scholar
  5. 5.
    Scagliotti GV, Parikh P, von Pawel J et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543–3551CrossRefPubMedGoogle Scholar
  6. 6.
    Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C (2013) PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 31:2895–2902CrossRefPubMedGoogle Scholar
  7. 7.
    Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550CrossRefPubMedGoogle Scholar
  8. 8.
    Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27:1227–1234CrossRefPubMedGoogle Scholar
  9. 9.
    Mok TS, Hsia TC, Tsai CM, Tsang K, Chang GC, Chang JW, Sirisinha T, Sriuranpong V, Thongprasert S, Chua DT, Moore N, Manegold C (2011) Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: a substudy of the Avastin in Lung trial. Asia Pac J Clin Oncol Suppl 2:4–12CrossRefGoogle Scholar
  10. 10.
    Niho S, Kunitoh H, Nokihara H, Horai T, Ichinose Y, Hida T, Yamamoto N, Kawahara M, Shinkai T, Nakagawa K, Matsui K, Negoro S, Yokoyama A, Kudoh S, Kiura K, Mori K, Okamoto H, Sakai H, Takeda K, Yokota S, Saijo N, Fukuoka M; JO19907 Study Group (2012) Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. Lung Cancer 76:362–367CrossRefPubMedGoogle Scholar
  11. 11.
    Cardona AF, Rojas L, Wills B, Arrieta O, Carranza H, Vargas C, Otero J, Cuello M, Corrales L, Martín C, Ortiz C, Franco S, Rosell R, CLICaP (2016) Pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab in Hispanic patients with non-squamous non-small cell lung cancer: outcomes according to thymidylate synthase expression. PLoS One 11:e0154293CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Zhou C, Wu YL, Chen G, Liu X, Zhu Y, Lu S, Feng J, He J, Han B, Wang J, Jiang G, Hu C, Zhang H, Cheng G, Song X, Lu Y, Pan H, Zheng W, Yin AY (2015) BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer. J Clin Oncol 33:2197–2204CrossRefPubMedGoogle Scholar
  13. 13.
    Barlesi F, Scherpereel A, Gorbunova V, Gervais R, Vikström A, Chouaid C, Chella A, Kim JH, Ahn MJ, Reck M, Pazzola A, Kim HT, Aerts JG, Morando C, Loundou A, Groen HJ, Rittmeyer A (2014) Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. Ann Oncol 25:1044–1052CrossRefPubMedGoogle Scholar
  14. 14.
    Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer Tur N, Kim JH, Ahn MJ, Aerts JG, Gorbunova V, Vikström A, Wong EK, Perez-Moreno P, Mitchell L, Groen HJ (2013) Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol 31:3004–3011CrossRefPubMedGoogle Scholar
  15. 15.
    Gautschi O, Rothschild SI, Li Q, Matter-Walstra K, Zippelius A, Betticher DC, Früh M, Stahel RA, Cathomas R, Rauch D, Pless M, Peters S, Froesch P, Zander T, Schneider M, Biaggi C, Mach N, Ochsenbein AF; Swiss Group for Clinical Cancer Research (2017). Bevacizumab plus pemetrexed versus pemetrexed alone as maintenance therapy for patients with advanced nonsquamous non-small-cell lung cancer: update from the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial. Clin Lung Cancer 18:303–309CrossRefPubMedGoogle Scholar
  16. 16.
    Yokoi T, Torii Y, Katashiba Y, Sugimoto H, Tanijiri T, Ogata M, Inagaki N, Kibata K, Hayashi M, Niki M, Shimizu T, Miyara T, Kurata T, Nomura S (2014) Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous non-small cell lung cancer. Oncol Lett 8:2453–2457CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957CrossRefPubMedGoogle Scholar
  18. 18.
    Wu SG, Yang CH, Yu CJ, Lee JH, Hsu YC, Chang YL, Shih JY, Yang PC (2011) Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations. Lung Cancer 72:333–339CrossRefPubMedGoogle Scholar
  19. 19.
    Okamoto I, Aoe K, Kato T, Hosomi Y, Yokoyama A, Imamura F, Kiura K, Hirashima T, Nishio M, Nogami N, Okamoto H, Saka H, Yamamoto N, Yoshizuka N, Sekiguchi R, Kiyosawa K, Nakagawa K, Tamura T (2013) Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer. Invest New Drugs 31:1275–1282CrossRefPubMedGoogle Scholar
  20. 20.
    Kimura T, Taniguchi H, Watanabe N, Saka H, Kogure Y, Shindo J, Ogasawara T, Kojima E, Hasegawa Y, Yamamoto M, Suzuki R, Ando M, Kondo M, Saito H (2016) Phase II study of carboplatin and pemetrexed in advanced EGFR-wild-type non-squamous non-small cell lung cancer: the central Japan lung study Group Trial 0906. Anticancer Res 36:1767–1771CrossRefPubMedGoogle Scholar
  21. 21.
    Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T (2004) Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64:8919–8923CrossRefPubMedGoogle Scholar
  22. 22.
    Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y, Fukuoka M (2007) Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-arm cooperative study in Japan. Ann Oncol 18:317–323CrossRefPubMedGoogle Scholar
  23. 23.
    Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, Teramukai S, Ohe Y, Kubota K, Williamson SK, Gautschi O, Lenz HJ, McLeod HL, Lara PN Jr, Coltman CA Jr, Fukuoka M, Saijo N, Fukushima M, Mack PC (2009) Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol 27:3540–3546CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Yang CH, Simms L, Park K, Lee JS, Scagliotti G, Orlando M (2010) Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer: results of an exploratory subgroup analysis of a phase III trial. J Thorac Oncol 5:688–695CrossRefPubMedGoogle Scholar
  25. 25.
    Ilhan-Mutlu A, Osswald M, Liao Y, Gömmel M, Reck M, Miles D, Mariani P, Gianni L, Lutiger B, Nendel V, Srock S, Perez-Moreno P, Thorsen F, von Baumgarten L, Preusser M, Wick W, Winkler F (2016) Bevacizumab prevents brain metastases formation in lung adenocarcinoma. Mol Cancer Ther 15:702–710CrossRefPubMedGoogle Scholar
  26. 26.
    Fu Y, Hu J, Du N, Jiao S, Li F, Li X, Ma J, Zhao H, Kang H (2016) Bevacizumab plus chemotherapy versus chemotherapy alone for preventing brain metastasis derived from advanced lung cancer. J Chemother 28:218–224CrossRefPubMedGoogle Scholar
  27. 27.
    Besse B, Le Moulec S, Mazières J, Senellart H, Barlesi F, Chouaid C, Dansin E, Bérard H, Falchero L, Gervais R, Robinet G, Ruppert AM, Schott R, Léna H, Clément-Duchêne C, Quantin X, Souquet PJ, Trédaniel J, Moro-Sibilot D, Pérol M, Madroszyk AC, Soria JC (2015) Bevacizumab in patients with nonsquamous non-small cell lung cancer and asymptomatic, untreated brain metastases (BRAIN): a nonrandomized, phase II study. Clin Cancer Res 21:1896–1903CrossRefPubMedGoogle Scholar
  28. 28.
    Zhu W, Røe OD, Wu C, Li W, Guo R, Gu Y, Liu Y, Shu Y, Chen X (2015) Activity of pemetrexed-based regimen as first-line chemotherapy for advanced non-small cell lung cancer with asymptomatic inoperable brain metastasis: a retrospective study. J Chemother 27:221–226CrossRefPubMedGoogle Scholar
  29. 29.
    Yoh K, Goto Y, Naito Y, Kishi K, Mori K, Hotta K, Hosomi Y, Yamada K, Tanai C, Tomizawa Y, Inoue A, Hasegawa Y, Nishio M, Ohashi Y, Kunitoh H (2017) Impact of maintenance therapy for patients with non-small cell lung cancer in a real-world setting. Anticancer Res 37:1507–1513CrossRefPubMedGoogle Scholar
  30. 30.
    Wang L, Wang R, Pan Y, Sun Y, Zhang J, Chen H (2014) The pemetrexed-containing treatments in the non-small cell lung cancer is −/low thymidylate synthase expression better than +/high thymidylate synthase expression: a meta-analysis. BMC Cancer 14:205CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Sun JM, Ahn JS, Jung SH, Sun J, Ha SY, Han J, Park K, Ahn MJ (2015) Pemetrexed plus cisplatin versus gemcitabine plus cisplatin according to thymidylate synthase expression in nonsquamous non-small-cell lung cancer: a biomarker-stratified randomized phase II trial. J Clin Oncol 33:2450–2456CrossRefPubMedGoogle Scholar
  32. 32.
    Ishikura N, Yanagisawa M, Noguchi-Sasaki M, Iwai T, Yorozu K, Kurasawa M, Sugimoto M, Yamamoto K (2017) Importance of bevacizumab maintenance following combination chemotherapy in human non-small cell lung cancer xenograft models. Anticancer Res 37:623–629CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Toshirou Fukushima
    • 1
  • Yuuki Wakatsuki
    • 1
  • Takashi Kobayashi
    • 1
  • Kei Sonehara
    • 2
  • Kazunari Tateishi
    • 2
  • Manabu Yamamoto
    • 3
  • Takeshi Masubuchi
    • 3
  • Fumiaki Yoshiike
    • 4
  • Kazuya Hirai
    • 4
  • Tsutomu Hachiya
    • 5
  • Tomonobu Koizumi
    • 1
  1. 1.Department of Comprehensive Cancer TherapyShinshu University School of MedicineNaganoJapan
  2. 2.First Department of Internal MedicineShinshu University School of MedicineMatsumotoJapan
  3. 3.Department of Pulmonary DiseaseNagano Red Cross HospitalNaganoJapan
  4. 4.Department of Pulmonary DiseaseNagano Municipal HospitalNaganoJapan
  5. 5.Department of Pulmonary DiseaseSuwa Red Cross HospitalSuwaJapan

Personalised recommendations